An Observational Study of MabThera/Rituxan (Rituximab) in Patients With Sero-Positive Rheumatoid Arthritis Who Are Non-Responders or Intolerant to a Single TNF-Inhibitor (PORTSMAB)

Portuguese Observational Re-Treatment Study of MabThera (PORTSMAB) - A Two-centre Observational Study in Sero-positive Rheumatoid Arthritis (RA) Patients Who Are Non-responders or Intolerant to a Single Tumor Necrosis Factor (TNF) Inhibitor

This observational study will assess the long-term efficacy and safety of MabThera/Rituxan in routine clinical practice in patients with sero-positive rheumatoid arthritis who are non-responders or intolerant to a single tumour necrosis factor (TNF) inhibitor. Data will be collected from each patient over 2 years.

Inclusion Criteria:

• Adult patients, >/= 18 years of age
• Rheumatoid arthritis positive for rheumatoid factor and/or anti-CCP
• Non-responder or intolerant to single TNF-inhibitor therapy
• Initiating treatment with MabThera/Rituxan

Exclusion Criteria:

• Contra-indications to MabThera/Rituxan therapy